Patients will be included with a stable but active disease (as defined Diagnosis of systemic sclerosis according to ACR/EULAR classification by EUSTAR ≥2.5) or to patients with a worsening disease despite low dose steroids and at least 2 immunosuppressive treatment including DMARDs (methotrexate research hub

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

This study is testing a new cell therapy called SCLEROCAR for severe systemic sclerosis. It aims to see if this treatment, using special T-cells, can improve skin and organ symptoms in people whose condition hasn't responded to usual medicines. Researchers want to understand its safety and how well it works.